B-cell Blood Cancer Marker Study Using Flow Cytometry
Part of Blood & lymphatic, Cancer clinical trials.
This study examines specific markers (PD-L1 and CD276) on blood cancer cells in newly diagnosed patients with B-cell leukemias or lymphomas. Understanding these markers may help doctors better understand your cancer and develop better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed (not previously treated) with a B-cell blood cancer
- Your cancer is either acute lymphoblastic leukemia (ALL) or a chronic B-cell disorder like chronic lymphocytic leukemia (CLL)
- You have not yet started chemotherapy treatment
- You do not have any other type of cancer
- You do not have an autoimmune disease (a condition where your immune system attacks your own body)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two proteins on cancer cells (CD305 and CD85d) to better understand types of B-cell blood cancers. Results may help doctors tailor future treatments.
This study looks at inflammatory markers in the blood of people newly diagnosed with B-cell neoplasms (a group of blood cancers and related disorders). It aims to better understand how these markers relate to the disease and may help guide future care.
This study looks at simple blood test results from people newly diagnosed with acute lymphoblastic leukemia (ALL) to see if certain markers help understand the disease better.
This study looks at whether certain blood cell tests (reticulocyte parameters) can early detect how well your bone marrow is making red blood cells in people newly diagnosed with chronic B-cell cancers. It aims to improve monitoring before standard treatments begin.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.